1 Min Read
May 18 (Reuters) - Spark Therapeutics Inc
* Spark Therapeutics completes rolling biologics license application submission to FDA for investigational gene therapy voretigene neparvovec Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.